ClinicalTrials.gg
Drug

AB928 clinical trials

Also written AB928 and Etrumadenant.

studies test it
18
open now
3
in phase 3
0
first study started
2017

How each study uses AB928 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the AB928 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

AB928
14
GS-0928
1

Other names

Etrumadenant
13

Studies by the year they started

18 studies that test it; most in 2023 (5)

Studies that test AB928, by start year
YearStudies
20171
20183
20191
20201
20213
20223
20235
20241

By phase

A phase 1/2 study counts in both.

Phase 1
11
Phase 2
11

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 11 · Other 7

Arcus Biosciences, Inc. (8) · Hoffmann-La Roche (2) · Washington University School of Medicine (1) · Memorial Sloan Kettering Cancer Center (1) · M.D. Anderson Cancer Center (1) · Gilead Sciences (1) · Weill Medical College of Cornell University (1) · Gulam Manji (1)

Often tested with

Tested in the same studies.

Zimberelimab (9) · Bevacizumab (3) · Domvanalimab (2) · Paclitaxel (2) · Selicrelumab (2) · Quemliclustat (2) · Sacituzumab govitecan (1) · Carboplatin (1)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 6

Studies that test AB928.

Studies

Open first, then newest update. How each study uses AB928 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 18

Given beside what is tested · 4 — AB928 is usual care or a partner of the new treatment

Codes

What other systems call AB928 · ClinicalTrials.gg INT018287

  • UNII (FDA) W0ZE0NT8IFETRUMADENANTConfirmed FDA, Wikidata
  • Wikidata Q66977586AB928Confirmed FDA, Wikidata
  • DrugBank DB17506One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.